An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

• Status: Withdrawn
• Trial end date: 2013-04-01

Summary

The purpose of this study is to evaluate tapentadol Extended Release (ER) in the treatment of moderate to severe chronic pain in participants with a diagnosis of chronic low back pain (LBP) or osteoarthritis (OA) of the hip or knee after conversion from hydrocodone, oxycodone Controlled Release (CR), and/or morphine Sustained Release (SR).

• Phase: Phase 4

Details

• Lead Sponsor: Janssen Scientific Affairs, LLC
• Treatments: Hydrocodone; Morphine; Oxycodone; Tapentadol